Jefferies initiates Gyre Therapeutics stock with Buy rating, $16 target

Jefferies initiated coverage on Gyre Therapeutics (NASDAQ:GYRE) with a Buy rating and a $16 price target, citing the global commercial biotech's strong sales in China and promising anti-fibrosis pipeline. The company's lead compound, hydronidone, successfully met its Phase 3 primary endpoint for fibrosis regression in chronic hepatitis B, positioning it for a potential first-in-class launch in China by 2026, while also planning Phase 2 trials for U.S. MASH and fibrosis indications by year-end 2025. With a market capitalization of $649 million, $102 million in LTM revenue, and impressive 96% gross margins, Gyre presents significant commercial potential, also drawing a Buy rating from H.C. Wainwright.

Analysis

Jefferies initiated coverage on Gyre Therapeutics (NASDAQ:GYRE) with a Buy rating and a $16.00 price target, indicating significant upside potential from its current trading price of $7.15. This positive sentiment is echoed by H.C. Wainwright, which also issued a Buy rating with an $18.00 price target, aligning with a broader consensus range of $18 to $20. Gyre is identified as a global commercial biotech company with expanding sales in China, specializing in anti-fibrosis treatments.

The company demonstrates robust commercial potential, evidenced by a $649 million market capitalization, $102 million in last twelve-month revenue, and impressive 96% gross margins, alongside moderate debt levels. Its lead compound, hydronidone, successfully met its Phase 3 primary endpoint for fibrosis regression in chronic hepatitis B (CHB), positioning it for a potential first-in-class launch in China by 2026. Additionally, Gyre plans to advance its pipeline into U.S. MASH and fibrosis indications, with Phase 2 trials anticipated by year-end 2025.

Strategic developments further underpin the company's outlook, including the appointment of Dan Weng, M.D., to its Board of Directors, effective August 18, 2025, bringing extensive industry experience. The mechanism of action for Gyre’s treatments is noted as disease etiology agnostic, suggesting versatility for combination or sequential therapy. InvestingPro data assigns a "Fair" overall financial health score, indicating a stable operational base for these growth initiatives.

Key Decisions for Investors

• Investors should consider the significant upside potential indicated by multiple analyst price targets, particularly given the successful Phase 3 trial for hydronidone and its projected 2026 China launch.
• Monitor the progress of U.S. Phase 2 trials for MASH and fibrosis indications, as these represent key catalysts for future growth and market expansion.
• Evaluate the company's strong financial fundamentals, including its high gross margins and moderate debt, as a foundation for sustained pipeline development and commercialization efforts.